Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase 3 2Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Screening 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

pembrolizumab 130Carboplatin 127Cisplatin 118Paclitaxel 99Gemcitabine 87Specimen Handling 80Magnetic Resonance Spectroscopy 80Docetaxel 70Dexamethasone 62Cyclophosphamide 61Pemetrexed 59Capecitabine 56Bevacizumab 56durvalumab 52Oxaliplatin 52Fluorouracil 50Doxorubicin 49Radiotherapy 48Leucovorin 45Radiation 44Rituximab 43Lenalidomide 42Vincristine 39Etoposide 36Nivolumab 34atezolizumab 33Letrozole 32130-nm albumin-bound paclitaxel 32Irinotecan 31Prednisone 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Genetic Testing × 90 days × Clear all
NCT06058377 2026-05-27

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
3,680 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT03233191 2026-05-05

Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
108,508 enrolled
Breast

Breast Screening

Data powered by HemOnc (CC BY 4.0) Colophon âš¡